181 related articles for article (PubMed ID: 11197076)
1. Effect of buthionine sulphoximine, glutathione and methimazole on the renal disposition of cisplatin and on cisplatin-induced nephrotoxicity in rats: pharmacokinetic-toxicodynamic analysis.
Hanada K; Mukasa Y; Nomizo Y; Ogata H
J Pharm Pharmacol; 2000 Dec; 52(12):1483-90. PubMed ID: 11197076
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin.
Hanada K; Ninomiya K; Ogata H
J Pharm Pharmacol; 2000 Nov; 52(11):1345-53. PubMed ID: 11186242
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of methimazole against cisplatin-induced nephrotoxicity in rats.
Bräunlich H; Appenroth D; Fleck C
J Appl Toxicol; 1997; 17(1):41-5. PubMed ID: 9048226
[TBL] [Abstract][Full Text] [Related]
4. Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats.
Hanada K; Odaka K; Kudo A; Ogata H
Pharm Res; 1999 Oct; 16(10):1589-95. PubMed ID: 10554102
[TBL] [Abstract][Full Text] [Related]
5. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin.
Zhang JS; Imai T; Otagiri M
Arch Toxicol; 2000 Aug; 74(6):300-7. PubMed ID: 11005675
[TBL] [Abstract][Full Text] [Related]
6. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
Nagai N; Ogata H
Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
[TBL] [Abstract][Full Text] [Related]
7. Methimazole protection of rats against chemically induced kidney damage in vivo.
Sausen PJ; Elfarra AA; Cooley AJ
J Pharmacol Exp Ther; 1992 Jan; 260(1):393-401. PubMed ID: 1731048
[TBL] [Abstract][Full Text] [Related]
8. Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats.
Humanes B; Lazaro A; Camano S; Moreno-Gordaliza E; Lazaro JA; Blanco-Codesido M; Lara JM; Ortiz A; Gomez-Gomez MM; Martín-Vasallo P; Tejedor A
Kidney Int; 2012 Sep; 82(6):652-63. PubMed ID: 22718191
[TBL] [Abstract][Full Text] [Related]
9. Methimazole protection of rats against gentamicin-induced nephrotoxicity.
Elfarra AA; Duescher RJ; Sausen PJ; O'Hara TM; Cooley AJ
Can J Physiol Pharmacol; 1994 Oct; 72(10):1238-44. PubMed ID: 7882190
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cisplatin-induced nephrotoxicity in rats by buthionine sulfoximine, a glutathione synthesis inhibitor.
Mayer RD; Lee KE; Cockett AT
Cancer Chemother Pharmacol; 1987; 20(3):207-10. PubMed ID: 2890443
[TBL] [Abstract][Full Text] [Related]
11. Buthionine sulfoximine (BSO) and N-(3,5-dichlorophenyl)succinimide nephrotoxicity: temporal aspects of BSO administration and BSO effects on renal transport systems.
Rankin GO; Beers KW; Teets VJ; Nicoll DW; Anestis DK
Toxicology; 1997 Feb; 117(2-3):207-17. PubMed ID: 9057900
[TBL] [Abstract][Full Text] [Related]
12. Is thallium-induced nephrotoxicity in rats connected with riboflavin and/or GSH?--reconsideration of hypotheses on the mechanism of thallium toxicity.
Appenroth D; Winnefeld K
J Appl Toxicol; 1999; 19(1):61-6. PubMed ID: 9989479
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of cisplatin toxicity by buthionine sulfoximine, a glutathione-depleting agent, in mice.
Ishikawa M; Takayanagi Y; Sasaki K
Res Commun Chem Pathol Pharmacol; 1990 Jan; 67(1):131-41. PubMed ID: 2326543
[TBL] [Abstract][Full Text] [Related]
14. [Experimental study on the effects of BSO, GSH, vitamin C and DMPS on the nephrotoxicity induced by mercury].
Zhao-Fa X; Jing-Hua Y; Jia-Ming Y; Zhong-Wei Y
Wei Sheng Yan Jiu; 2005 Sep; 34(5):533-6. PubMed ID: 16329589
[TBL] [Abstract][Full Text] [Related]
15. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
16. The deleterious effect of buthionine sulfoximine, a glutathione-depleting agent, on the cisplatin toxicity in mice.
Ishikawa M; Takayanagi Y; Sasaki K
Jpn J Pharmacol; 1990 Apr; 52(4):652-5. PubMed ID: 2342233
[TBL] [Abstract][Full Text] [Related]
17. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.
Nagai N; Hotta K; Yamamura H; Ogata H
Cancer Chemother Pharmacol; 1995; 36(5):404-10. PubMed ID: 7634382
[TBL] [Abstract][Full Text] [Related]
18. Nephrotoxicity of thiabendazole in mice depleted of glutathione by treatment with DL-buthionine sulphoximine.
Mizutani T; Ito K; Nomura H; Nakanishi K
Food Chem Toxicol; 1990 Mar; 28(3):169-77. PubMed ID: 2344991
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-Pharmacodynamic Analysis of Cisplatin with Hydration and Mannitol Diuresis: The Contribution of Urine Cisplatin Concentration to Nephrotoxicity.
Fukushima K; Okada A; Oe H; Hirasaki M; Hamori M; Nishimura A; Shibata N; Sugioka N
Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):193-203. PubMed ID: 28913815
[TBL] [Abstract][Full Text] [Related]
20. Improved use of buthionine sulfoximine to prevent cisplatin nephrotoxicity in rats.
Mayer RD; Lee KE; Cockett AT
J Cancer Res Clin Oncol; 1989; 115(5):418-22. PubMed ID: 2808478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
